Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation

Robert J. Fontana, Eric A. Hughes, Henry Appelman, Robert Hindes, Dessislava Dimitrova, Marc Bifano – 18 June 2012 – A recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) can lead to accelerated allograft injury and fibrosis. The aim of this article is to report the first ever use of daclatasvir (DCV; also known as BMS‐790052), a potent orally administered nonstructural 5A replication complex inhibitor, in combination with peginterferon α (PEG‐IFNα) and ribavirin in an LT recipient.

Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection

Victoria M. Velazquez, Huiming Hon, Chris Ibegbu, Stuart J. Knechtle, Allan D. Kirk, Arash Grakoui – 18 June 2012 – Chronic hepatitis C virus (HCV) infection is a serious disease that can result in numerous long‐term complications leading to liver failure or death. Approximately 80% of people fail to clear their infection, largely as the result of weak, narrowly targeting or waning antiviral T‐cell responses.

Transcriptomic profiling reveals hepatic stem‐like gene signatures and interplay of miR‐200c and epithelial‐mesenchymal transition in intrahepatic cholangiocarcinoma

Naoki Oishi, Mia R. Kumar, Stephanie Roessler, Junfang Ji, Marshonna Forgues, Anuradha Budhu, Xuelian Zhao, Jesper B. Andersen, Qing‐Hai Ye, Hu‐Liang Jia, Lun‐Xiu Qin, Taro Yamashita, Hyun Goo Woo, Yoon Jun Kim, Shuichi Kaneko, Zhao‐You Tang, Snorri S. Thorgeirsson, Xin Wei Wang – 18 June 2012 – Intrahepatic cholangiocellular carcinoma (ICC) is the second most common type of primary liver cancer. However, its tumor heterogeneity and molecular characteristics are largely unknown.

HNF1B deficiency causes ciliary defects in human cholangiocytes

Philip Roelandt, Aline Antoniou, Louis Libbrecht, Werner Van Steenbergen, Wim Laleman, Chris Verslype, Schalk Van der Merwe, Frederik Nevens, Rita De Vos, Evelyne Fischer, Marco Pontoglio, Frédéric Lemaigre, David Cassiman – 18 June 2012 – Heterozygous deletion or mutation in hepatocyte nuclear factor 1 homeobox B/transcription factor 2 (HNF1B/TCF2) causes renal cyst and diabetes syndrome (OMIM #137920). Mice with homozygous liver‐specific deletion of Hnf1β revealed that a complete lack of this factor leads to ductopenia and bile duct dysplasia, in addition to mild hepatocyte defects.

Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients' poor recurrence‐free survival after hepatectomy

Sheng‐Xian Yuan, Fu Yang, Yuan Yang, Qi‐Fei Tao, Jin Zhang, Gang Huang, Yun Yang, Ruo‐Yu Wang, Sen Yang, Xi‐Song Huo, Ling Zhang, Fang Wang, Shu‐Han Sun, Wei‐Ping Zhou – 18 June 2012 – Survival of patients with hepatocellular carcinoma (HCC) remains poor, which is largely attributed to active angiogenesis. However, the mechanisms underlying angiogenesis in HCC remain to be discovered. In this study, we found that long noncoding RNA associated with microvascular invasion in HCC (lncRNA MVIH) (lncRNA associated with microvascular invasion in HCC) was generally overexpressed in HCC.

HNF1B deficiency causes ciliary defects in human cholangiocytes

Philip Roelandt, Aline Antoniou, Louis Libbrecht, Werner Van Steenbergen, Wim Laleman, Chris Verslype, Schalk Van der Merwe, Frederik Nevens, Rita De Vos, Evelyne Fischer, Marco Pontoglio, Frédéric Lemaigre, David Cassiman – 18 June 2012 – Heterozygous deletion or mutation in hepatocyte nuclear factor 1 homeobox B/transcription factor 2 (HNF1B/TCF2) causes renal cyst and diabetes syndrome (OMIM #137920). Mice with homozygous liver‐specific deletion of Hnf1β revealed that a complete lack of this factor leads to ductopenia and bile duct dysplasia, in addition to mild hepatocyte defects.

Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents

Heiner Wedemeyer, Donald M. Jensen, Eliot Godofsky, Nina Mani, Jean‐Michel Pawlotsky, Veronica Miller, on behalf of the Definitions/Nomenclature Working Group* of the HCV DrAG (HCV Drug Development Advisory Group), under the auspices of the Forum for Collaborative HIV Research – 18 June 2012 – Outdated virological response terms used at key trial timepoints in clinical trials with first‐generation direct‐acting antivirals plus pegylated interferon and ribavirin have failed to keep pace with hepatitis C virus (HCV) drug development.

Subscribe to